A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer

Cao, Weibo; Tang, Quanying; Zeng, Jingtong; Jin, Xin; Zu, Lingling; Xu, Song

doi:10.3390/cancers15184561

Cited by 11 publications

(10 citation statements)

References 165 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, between 6 and 24 months after the primary tumor, 52.3 percents of triple-negative metastases are discovered, 24 percents of metastases are discovered for HER2+ and 12 percent of metastases are discovered for HR+HER2- 46 . For a lung cancer is less than 2 years and this time corresponds to an early recurrence observed in small cell lung cancer 47 , 48 . For a prostate cancer .…”

Section: Analytical and Numerical Resultsmentioning

confidence: 99%

Dynamics of a diffusive model for cancer stem cells with time delay in microRNA-differentiated cancer cell interactions and radiotherapy effects

Essongo,

Mvogo,

Ben-Bolie

2024

Sci Rep

View full text Add to dashboard Cite

Understand the dynamics of cancer stem cells (CSCs), prevent the non-recurrence of cancers and develop therapeutic strategies to destroy both cancer cells and CSCs remain a challenge topic. In this paper, we study both analytically and numerically the dynamics of CSCs under radiotherapy effects. The dynamical model takes into account the diffusion of cells, the de-differentiation (or plasticity) mechanism of differentiated cancer cells (DCs) and the time delay on the interaction between microRNAs molecules (microRNAs) with DCs. The stability of the model system is studied by using a Hopf bifurcation analysis. We mainly investigate on the critical time delay $$\tau _{c}$$ τ c , that represents the time for DCs to transform into CSCs after the interaction of microRNAs with DCs. Using the system parameters, we calculate the value of $$\tau _{c}$$ τ c for prostate, lung and breast cancers. To confirm the analytical predictions, the numerical simulations are performed and show the formation of spatiotemporal circular patterns. Such patterns have been found as promising diagnostic and therapeutic value in management of cancer and various diseases. The radiotherapy is applied in the particular case of prostate model. We calculate the optimum dose of radiation and determine the probability of avoiding local cancer recurrence after radiotherapy treatment. We find numerically a complete eradication of patterns when the radiotherapy is applied before a time $$t < \tau _{c}$$ t < τ c . This scenario induces microRNAs to act as suppressors as experimentally observed in prostate cancer. The results obtained in this paper will provide a better concept for the clinicians and oncologists to understand the complex dynamics of CSCs and to design more efficacious therapeutic strategies to prevent the non-recurrence of cancers.

show abstract

Section: Analytical and Numerical Resultsmentioning

confidence: 99%

Dynamics of a diffusive model for cancer stem cells with time delay in microRNA-differentiated cancer cell interactions and radiotherapy effects

Essongo,

Mvogo,

Ben-Bolie

2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Conversely, inhibitors of PD-L1 or PD-1 can substantially increase patient survival, and detectable perioperative ctDNA is also correlated with poorer survival outcomes. Elevated CEA levels in circulation before and after surgery predicted significantly reduced survival outcomes [102].…”

Section: Quality Of Evidencementioning

confidence: 99%

Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review

Restrepo,

Martínez Guevara,

Pareja López

et al. 2024

Cancers

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) comprises approximately 85% of all lung cancer cases, often diagnosed at advanced stages, which diminishes the effective treatment options and survival rates. This systematic review assesses the utility of emerging biomarkers—circulating tumor DNA (ctDNA), microRNAs (miRNAs), and the blood tumor mutational burden (bTMB)—enhanced by next-generation sequencing (NGS) to improve the diagnostic accuracy, prognostic evaluation, and treatment strategies in NSCLC. Analyzing data from 37 studies involving 10,332 patients from 2020 to 2024, the review highlights how biomarkers like ctDNA and PD-L1 expression critically inform the selection of personalized therapies, particularly beneficial in the advanced stages of NSCLC. These biomarkers are critical for prognostic assessments and in dynamically adapting treatment plans, where high PD-L1 expression and specific genetic mutations (e.g., ALK fusions, EGFR mutations) significantly guide the use of targeted therapies and immunotherapies. The findings recommend integrating these biomarkers into standardized clinical pathways to maximize their potential in enhancing the treatment precision, ultimately fostering significant advancements in oncology and improving patient outcomes and quality of life. This review substantiates the prognostic and predictive value of these biomarkers and emphasizes the need for ongoing innovation in biomarker research.

show abstract

“…139,140 Thus far, more CAR-T studies have focused primarily on NSCLC. 141,142 The most common target antigens of NSCLC include human EGFRs, mesothelin, mucin 1, PD-L1, 143 CEAs, 144 and HER2. 145 As a result, these antigens are potentially novel targets for NSCLC treatment.…”

Section: Another New Strategy For Treating Nsclc Is Car-t Therapymentioning

confidence: 99%

The DC–T cell axis is an effective target for the treatment of non‐small cell lung cancer

Wang,

Zhang,

Cui

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

The dendritic cell (DC)‐T cell axis is a bridge that connects innate and adaptive immunities. The initial immune response against tumors is mainly induced by mature antigen‐presenting DCs. Enhancing the crosstalk between DCs and T cells may be an effective approach to improve the immune response to non‐small cell lung cancer (NSCLC). In this article, a review was made of the interaction between DCs and T cells in the treatment of NSCLC and how this interaction affects the treatment outcome.

show abstract

A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer

Cited by 11 publications

References 165 publications

Dynamics of a diffusive model for cancer stem cells with time delay in microRNA-differentiated cancer cell interactions and radiotherapy effects

Dynamics of a diffusive model for cancer stem cells with time delay in microRNA-differentiated cancer cell interactions and radiotherapy effects

Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review

The DC–T cell axis is an effective target for the treatment of non‐small cell lung cancer

Contact Info

Product

Resources

About